New obesity drug combo shows promise in curbing appetite
NCT ID NCT06207877
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study tested whether a combination of two medicines, cagrilintide and semaglutide (called CagriSema), can reduce how much people eat and their appetite. 62 adults with overweight or obesity were randomly assigned to receive either CagriSema or a placebo for about 32 weeks. The main goal was to measure changes in food intake during meals and snacks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Parexel International GmbH
Berlin, 14050, Germany
Conditions
Explore the condition pages connected to this study.